Key Events This Week
9 Feb: Mildly bearish technical shift amid mixed momentum
10 Feb: Technical momentum shifts to sideways trend
12 Feb: Mojo Grade upgraded to Buy on strong fundamentals
12 Feb: Technical momentum signals mild bullish outlook
13 Feb: Technical momentum shifts to sideways amid mixed signals
9 February 2026: Mildly Bearish Technical Shift Amid Mixed Momentum
Sun Pharmaceutical Industries Ltd began the week with a subtle shift from a sideways to a mildly bearish technical trend. The stock closed at Rs.1,704.60, up 0.58% on the day, despite technical indicators such as the MACD and KST suggesting caution. The weekly MACD showed bearish momentum, while the RSI remained neutral, indicating no extreme overbought or oversold conditions. The stock traded within a narrow range, reflecting limited volatility as investors digested mixed signals.
Volume was robust at 102,093 shares, but the On-Balance Volume (OBV) indicator was mildly bearish on the weekly chart, signalling that volume trends did not strongly support upward price movement. The stock’s performance contrasted with the Sensex’s 1.04% gain, underperforming the benchmark on this day.
10 February 2026: Technical Momentum Shifts to Sideways Trend
On 10 February, Sun Pharma’s technical momentum transitioned from mildly bearish to a sideways trend, reflecting consolidation amid mixed market signals. The stock closed at Rs.1,707.55, a modest gain of 0.17%, with volume declining to 68,222 shares. Key indicators such as the MACD remained bearish on weekly charts but showed signs of stabilisation, while the RSI stayed neutral.
Daily moving averages turned mildly bullish, suggesting some short-term buying interest, though the broader technical landscape remained cautious. The stock outperformed the Sensex’s 0.25% gain, continuing to show resilience despite sector headwinds. Investors remained watchful for a breakout from this consolidation phase.
This week's disclosed pick, a Large Cap from NBFC, comes with precise Target Price and analysis. Check if you're positioned right for this opportunity!
- - Precise target price set
- - Weekly selection live
- - Position check opportunity
12 February 2026: Mojo Grade Upgraded to Buy on Strong Fundamentals
MarketsMOJO upgraded Sun Pharmaceutical Industries Ltd from Hold to Buy on 11 February 2026, reflecting improved fundamentals and a shift to a mildly bullish technical outlook. The company’s Mojo Score rose to 72.0, supported by strong quality metrics including a low debt profile, healthy return on equity of 15.21%, and consistent sales growth of 11.37% annually.
Financially, Sun Pharma reported net sales of Rs.15,520.54 crores in the latest quarter, with cash and equivalents of Rs.12,257.42 crores and an inventory turnover ratio of 5.21 times. Institutional investors hold a significant 36.94% stake, underscoring confidence in the company’s prospects.
Despite a premium valuation with a Price to Book ratio of 5.3 and a PEG ratio of 11.5, the upgrade reflects the stock’s robust operational performance and improving technical signals. The stock closed at Rs.1,714.65 on 12 February, up 0.23%, with daily moving averages turning mildly bullish and On-Balance Volume showing accumulation.
12 February 2026: Technical Momentum Signals Mild Bullish Outlook
Alongside the rating upgrade, technical momentum shifted from sideways to mildly bullish on 12 February. The stock traded in a narrow range between Rs.1,702.45 and Rs.1,715.00, closing at Rs.1,709.95, a 0.14% gain. While the weekly MACD remained bearish, the monthly MACD was mildly bearish, indicating stabilising momentum.
Daily moving averages crossed positively, and the On-Balance Volume indicator was mildly bullish on the weekly chart, suggesting increased buying interest. However, the Know Sure Thing (KST) indicator remained mildly bearish, reflecting some lingering caution. Bollinger Bands remained flat, signalling limited volatility and a consolidation phase.
Thinking about Sun Pharmaceutical Industries Ltd? Our real-time Verdict report breaks down everything – from financial health and peer comparison to technical signals and fair valuation for this large-cap stock!
- - Real-time Verdict available
- - Financial health breakdown
- - Fair valuation calculated
13 February 2026: Technical Momentum Shifts to Sideways Amid Mixed Signals
On the final trading day of the week, Sun Pharma’s technical momentum shifted from mildly bullish back to sideways. The stock closed at Rs.1,698.10, down 0.97% intraday but ending the week with a slight gain of 0.20%. Volume was subdued at 15,605 shares, reflecting cautious trading.
Key indicators such as the MACD remained bearish on weekly charts and mildly bearish on monthly charts, while the RSI stayed neutral. The Know Sure Thing (KST) indicator was mildly bearish, and Bollinger Bands suggested consolidation with limited volatility. On-Balance Volume showed mixed signals, mildly bullish weekly but bearish monthly, indicating uncertainty in volume trends.
Dow Theory analysis confirmed no clear trend on weekly or monthly timeframes, reinforcing the sideways momentum narrative. Despite this, the stock outperformed the Sensex’s 1.40% decline on the day, highlighting relative resilience amid broader market weakness.
Weekly Price Performance Comparison
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-02-09 | Rs.1,704.60 | +0.58% | 37,113.23 | +1.04% |
| 2026-02-10 | Rs.1,707.55 | +0.17% | 37,207.34 | +0.25% |
| 2026-02-11 | Rs.1,710.65 | +0.18% | 37,256.72 | +0.13% |
| 2026-02-12 | Rs.1,714.65 | +0.23% | 37,049.40 | -0.56% |
| 2026-02-13 | Rs.1,698.10 | -0.97% | 36,532.48 | -1.40% |
Key Takeaways
Positive Signals: The upgrade to a Buy rating by MarketsMOJO on 11 February 2026 was supported by strong fundamentals including robust net sales growth, low debt, and healthy return on equity. Daily moving averages and On-Balance Volume trends showed mild bullish momentum midweek, indicating accumulation by investors. The stock outperformed the Sensex over the week, demonstrating relative strength amid a broadly declining market.
Cautionary Signals: Despite the upgrade, several technical indicators such as the MACD and Know Sure Thing remained bearish or mildly bearish on weekly and monthly charts, signalling subdued momentum. The sideways trend and neutral RSI readings suggest consolidation rather than a clear directional move. Valuation metrics remain elevated, with a high Price to Book and PEG ratio, implying that the stock is priced for growth which may limit near-term upside.
Volume and Volatility: Trading volumes declined through the week, with subdued activity on the last day, reflecting investor caution. Bollinger Bands remained flat, indicating limited volatility and a consolidation phase. Investors should monitor volume and momentum indicators closely for signs of a breakout or breakdown.
Conclusion
Sun Pharmaceutical Industries Ltd’s week was characterised by a delicate balance between cautious optimism and technical uncertainty. The stock’s modest 0.20% gain outpaced the Sensex’s 0.54% decline, supported by a fundamental upgrade and mild bullish technical signals midweek. However, mixed momentum indicators and sideways price action suggest a consolidation phase rather than a decisive trend.
Investors should remain attentive to shifts in key technical indicators such as MACD crossovers, volume trends, and moving average behaviour to identify potential directional moves. The company’s strong fundamentals and leadership position in the Pharmaceuticals & Biotechnology sector provide a solid foundation, but elevated valuations and mixed technical signals counsel prudence in the near term.
Overall, Sun Pharma’s performance this week reflects a stock in transition, balancing positive fundamental news with a cautious technical backdrop, warranting close monitoring in the coming weeks.
Unlock special upgrade rates for a limited period. Start Saving Now →
